News Search Results
May 16, 2025, 09:43 ET Alamar Biosciences Memperluas NULISAseq™ CNS Disease Panel 120 dengan Terobosan Uji pTau yang Berasal Dari Otak dan Berbasis Darah
perusahaan yang mendukung proteomik presisi untuk memungkinkan deteksi penyakit paling dini. Hari ini Alamar Biosciences mengumumkan perluasan NULISAseq™ CNS Disease Panel 120hingga mencakup tes baru untuk protein tau terfosforilasi (pTau) yang berasal dari otak. Panel yang telah disempurnakan ini sekarang
More news about: Alamar Biosciences, Inc.
May 16, 2025, 09:38 ET Alamar Biosciences社がNULISAseq™ CNS Disease Panel 120に画期的な血液ベースの脳由来pTauアッセイを追加
カリフォルニア州フリーモント, 2025年5月16日 /PRNewswire/ -- 病気の早期発見を可能にする精密プロテオミクスを推進するAlamar Biosciencesは本日、NULISAseq™ CNS Disease Panel 120を拡張し、脳由来リン酸化タウ（pTau）タンパク質向けの新しいアッセイを追加すると発表しました。強化されたパネルには、血液サンプルから直接測定された脳由来の pTau217、pTau181、pTau231、およびトータル・タウ（tTau）タンパク質が含まれており、神経変性疾患の研究にこれまでにない感度と特異性をもたらします。
More news about: Alamar Biosciences, Inc.
May 16, 2025, 09:07 ET Alamar Biosciences erweitert NULISAseq™ CNS Disease Panel 120 mit bahnbrechenden blutbasierten, aus dem Gehirn abgeleiteten pTau-Assays
Unternehmen, das die Präzisionsproteomik vorantreibt, um die früheste Erkennung von Krankheiten zu ermöglichen, gab heute die Erweiterung seines NULISAseq™ CNS Disease Panel 120 um neuartige Assays für vom Gehirn abgeleitete phosphorylierte Tau (pTau)-Proteine bekannt. Das erweiterte Panel umfasst nun die
More news about: Alamar Biosciences, Inc.
May 15, 2025, 16:34 ET Alamar Biosciences 擴展 NULISAseq™ CNS Disease Panel 120，推出破天荒以血液為基礎的腦部衍生 pTau 分析法
最近的證據突顯出能夠檢測腦源性 pTau 對於提高 AD 特異性的重要性。Alamar 的新型 CNS 試劑盒提供了前所未有的機會，可進一步提高這些生物標誌物的診斷準確性和臨床效用，這將對病人照護和臨床研究產生重大影響。」 Alamar Biosciences 將持續致力於與神經科學界合作，發掘生物標記的洞察分析，以推動早期診斷、病人分層分流及治療監控。 如需了解有關 NULISAseq CNS Disease Panel 120 和 Alamar Biosciences 蛋白質體解決方案組合的更多資訊，請瀏覽
More news about: Alamar Biosciences, Inc.
May 15, 2025, 16:03 ET NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update
use – in the manner that diabetes drugs are currently administered – could facilitate far broader clinical use of ketamine to treat life-threatening CNS diseases. NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. NRX-101:
More news about: NRx Pharmaceuticals, Inc.
May 15, 2025, 09:13 ET Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217,
More news about: Alamar Biosciences, Inc.
May 15, 2025, 09:13 ET Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217,
More news about: Alamar Biosciences, Inc.
May 15, 2025, 08:05 ET Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
May 15, 2025, 08:00 ET Kazia Therapeutics Highlights Recent Progress and Provides Business Update
study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
May 15, 2025, 06:09 ET Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences
animal models. Phase I clinical trial suggests that DZD8586 exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.
More news about: Dizal Pharmaceutical
May 14, 2025, 16:05 ET Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Upcoming Events page of the Company's website.ELVN-002 is a potent, highly selective, central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations The Company dosed
More news about: Enliven Therapeutics, Inc.
May 14, 2025, 09:00 ET Cohen & Steers and IDR Investment Management Partner to Launch Tactical Listed and Private Real Estate Strategy
YORK, May 14, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that the firm, in partnership with IDR Investment Management, LLC ("IDR"), has launched an innovative real estate strategy designed
More news about: Cohen & Steers, Inc.
May 14, 2025, 08:00 ET Alar Pharmaceuticals Announces First Patient Dosing in a Study of ALA-3000 (Extended-Release Ketamine Injection) for Treatment-Resistant Depression (TRD)
Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage pharmaceutical company dedicated to the development of long-acting injectables to treat CNS disorders, today announced the dosing of the first patient in the multiple ascending study of subcutaneous extended-release Ketamine (ALA-3000) for Treatment-Resistant
More news about: Alar Pharmaceuticals Inc.
May 14, 2025, 08:00 ET GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Professor, Department of Neurosurgery, Co-Director of Neurosurgical Oncology Timothy H. Chen, MD, Medical Director, CNS, Department of Radiation Oncology "This designation is a powerful acknowledgment of our commitment to advancing brain tumor care. Innovative
More news about: GT Medical Technologies
May 14, 2025, 07:13 ET FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
gene to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is structurally
More news about: NS Pharma, Inc.
May 14, 2025, 02:04 ET Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities
Research Organization (CRO) headquartered in the Netherlands (Zeist), and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States (Georgia), announce they have merged as a fully integrated
More news about: Julius Clinical Research
May 13, 2025, 08:03 ET HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics
among the first to bring ketamine treatment for central nervous system (CNS) disorders out of academic research settings and into clinical practice. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, transcranial magnetic stimulation
More news about: NRx Pharmaceuticals, Inc.
May 13, 2025, 07:05 ET REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is
More news about: REGENXBIO Inc.
May 12, 2025, 13:39 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
May 08, 2025, 16:28 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for April 2025
NEW YORK, May 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $87.5 billion as of April 30, 2025,
More news about: Cohen & Steers, Inc.
May 08, 2025, 07:05 ET REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
Mucopolysaccharidosis Type IIPresenter: Olivier Danos, Ph.D., Executive Vice President, Chief Scientific Officer, REGENXBIOSession: CNS Gene Delivery for Metabolic Diseases: History and ChallengesDate/Time: May 14, 8:00 a.m. CT Abstract
More news about: REGENXBIO Inc.
May 08, 2025, 07:00 ET Corero Network Security Appoints Adrian Crawley as VP of International Sales to Accelerate Global Expansion
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced the appointment of Adrian Crawley
More news about: Corero Network Security
May 07, 2025, 15:46 ET TechEnabler e AcessoLINE Telecom e Brasil TecPar reforçam parceria para garantir proteção contínua contra ataques DDoS
Edimburgo, Reino Unido, a Corero tem sede em Londres e está listada no mercado AIM da Bolsa de Valores de Londres (código: CNS) e no mercado OTCQX dos EUA (OTCQX: DDOSF).
More news about: TechEnabler
May 07, 2025, 12:00 ET Apertura Gene Therapy Showcases the Progress of its Novel Human Transferrin Receptor AAV Capsid, TfR1 CapX, and Preclinical Programs for Tuberous Sclerosis Complex (TSC) at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
vitro. TfR1 CapX's inherent efficiency in crossing the blood-brain barrier and achieving CNS-wide delivery enables this split intein strategy for TSC2. Apertura's TfR1 CapX unlocks opportunities to address other CNS diseases requiring delivery of large genes or novel gene editing payloads. "Apertura
More news about: Apertura Gene Therapy
May 07, 2025, 09:00 ET Mitsubishi Tanabe Pharma America Announces Presentations at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD)
combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at
More news about: Mitsubishi Tanabe Pharma America